{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-030816","form_type":"8-K","ticker":null,"cik":"0001008848","company_name":"Acorda Therapeutics, Inc.","filed_at":"2024-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.079076+00:00","generated_at":"2026-06-04T21:59:04.723040+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Acorda Therapeutics amends Bylaws to enhance director nomination procedures and conform to Delaware law","bullets":["Board adopted Amended and Restated Bylaws effective March 7, 2024.","Enhanced disclosure and procedural requirements for stockholder director nominations, including Rule 14a-19 compliance.","Updated provisions reflect recent amendments to Delaware General Corporation Law.","Includes clerical and conforming changes."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-030816","json":"https://secwatch.observer/filing/0000950170-24-030816.json","markdown":"https://secwatch.observer/filing/0000950170-24-030816.md","text":"https://secwatch.observer/filing/0000950170-24-030816.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1008848/000095017024030816/0000950170-24-030816-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1008848/000095017024030816/acor-20240307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T21:59:04.723040+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"facf11790415d26a40375a0de491e717bd212bd3","claim":"Acorda Therapeutics, Inc.: Adopted amended and restated bylaws effective immediately, enhancing disclosure and procedural requirements for stockholder director nominations and updating provisions to reflect Delaware law changes (effective 2024-03-07).","evidence_excerpt":"On March 7, 2024, the Board of Directors of Acorda Therapeutics, Inc. (the “Company”) adopted amendments to the Company’s Bylaws (the “Amended and Restated Bylaws”), which became effective immediately.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1008848/000095017024030816/0000950170-24-030816-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2024-03-07"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}